BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 14578760)

  • 1. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
    Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients.
    Ferraresso M; Tirelli A; Ghio L; Grillo P; Martina V; Torresani E; Edefonti A
    Pediatr Transplant; 2007 May; 11(3):296-300. PubMed ID: 17430486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
    Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
    Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.
    Larriba J; Imperiali N; Groppa R; Giordani C; Algranatti S; Redal MA
    Transplant Proc; 2010; 42(1):257-9. PubMed ID: 20172323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.
    Zhu HJ; Yuan SH; Fang Y; Sun XZ; Kong H; Ge WH
    Pharmacogenomics J; 2011 Jun; 11(3):237-46. PubMed ID: 20368718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
    Wang L; Li N; Wang MX; Lu SC
    Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.